Eric Halioua – President & CEO, PDC*line Pharma
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Address: Archimedesstraat 11 – B1000 Brussels,Belgium
Tel: +32 2 285 42 00
Web: http://www.apb.be/Content/Default.asp
The General Pharmaceutical Association (APB) is the umbrella federation of the Belgian associations of independent pharmacists. APB represents 90 percent of the pharmaceutical corps, which essentially covers the total of the corresponding independent pharmacists.
The activities of the APB includes the advocacy of its members as well as other forms of assistance and information to its members.
Under the control of the General Assembly shall determine the general policy of the Federal Council, which is followed by the Management Committee. This includes not only ‘contacts’ with the Federal Government, Regions, Communities and the official authorities, but also the representation in the lap of numerous committees both at regulatory level and in terms of the health of the drug delivery control.
The APB members provide services including legal assistance, social and economic information, scientific and pharmaceutical documentation, etc.
In addition, the Office for Drug Research (DGO) part of the APB. The core of this officially recognized and accredited laboratory analysis, monitoring and systematic, periodic rechecking of medicines and products with a quality label.
PDC*line Pharma’s Eric Halioula explains why he decided to establish a biotech in Belgium, outlines the progress that his immuno-oncology focused firm has made in clinical trials since our last…
Once primarily associated with dispensing medications alone, many pharmacies have now evolved into dynamic healthcare hubs, offering a diverse range of services that extend far beyond traditional prescription filling. Similarly,…
The concepts of patient-centricity and patient-centred healthcare systems have been much discussed in recent years but, in the opinion of Stefan Gijssels, there is still a long road to travel…
Pierre Boyer, GM at Servier BeLux for the past six years, outlines the unique characteristics and challenges of the Belgian market and shares the company’s 2030 strategy, its unique approach…
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Luc Van Gorp is president of the Christian Mutuality, Belgium’s largest health insurance fund. In a wide-ranging recent conversation with PharmaBoardroom, Van Gorp expanded on some of the key themes…
Xavier De Cuyper of the Federal Agency for Medicines & Health Products (FAMHP), Belgium’s drug regulator, explains the FAMHP’s pandemic response and lessons learned, how the Agency is keeping on…
As part of the EU’s Pharmaceutical Strategy for Europe, the European Commission has come out with a set of proposals to revise EU pharmaceutical legislation. The reforms, which aim to…
Gábor Sztaniszláv talks through the global relevance of Belux to Amgen’s operations, some of the challenging market access conditions at play – especially for orphan drugs -, and how the…
Marc Gryseels of BACHI, Belgium’s over-the-counter (OTC) medicines association, highlights the organisation’s mission and vision, the key trends at play within the Belgian consumer healthcare market, and his industry’s significant…
Despite the thriving life sciences ecosystem that has made Belgium one of the top European destinations for clinical trials, the country continues to grapple with considerable access challenges and remains…
pharma.be is the association of the Belgian R&D-based pharmaceutical industry, representing over 42,000 employees at 130 companies. CEO Caroline Ven outlines the crucial role that pharma.be and its members played…
See our Cookie Privacy Policy Here